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Abstract 
Replication kinetics and invasion characteristics of equine herpesvirus-1 and -3 (EHV-1/-3) in nasal and vaginal 
mucosae were compared using explants. The explants were cultured during 96 h with little change in viability. The 
tissues were inoculated with EHV-1 03P37 (neuropathogenic), 97P70 (abortigenic) and EHV-3 04P57, collected at 0, 
24, 48 and 72 h post inoculation (pi) and stained for viral antigens. Both EHV-1 and EHV-3 replicated in a plaquewise 
manner. The plaques were already observed at 24 h pi, their size increased over time and did not directly cross the 
basement membrane (BM). However, EHV-1 infected the monocytic cells (MC) and hijacked these cells to invade the 
lamina propria. In contrast, EHV-3 replication was fully restricted to epithelial cells; the virus did not breach the BM via 
a direct cell-to-cell spread nor used infected MC. EHV-1-induced plaques were larger in nasal mucosa compared to 
vaginal mucosa. The opposite was found for EHV-3-induced plaques. Both EHV-1 strains replicated with comparable 
kinetics in nasal mucosa. However, the extent of replication of the abortigenic strain in vaginal mucosa was signifi-
cantly higher than that of the neuropathogenic strain. Two-to-five-fold lower numbers of EHV-1-infected MC under-
neath the BM were found in vaginal mucosa than in nasal mucosa. Our study has shown that (i) EHV-1 has developed 
in evolution a predisposition for respiratory mucosa and EHV-3 for vaginal mucosa, (ii) abortigenic EHV-1 replicates 
better in vaginal mucosa than neuropathogenic EHV-1 and (iii) EHV-3 demonstrated a strict epithelial tropism whereas 
EHV-1 in addition hijacked MC to invade the lamina propria.
© 2016 Negussie et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Equine herpesvirus-1 (EHV-1) and equine herpesvirus-3 
(EHV-3) cause contagious diseases in equids worldwide 
[1, 2]. EHV-1 is responsible for respiratory disorders, 
abortion, neonatal foal death, myeloencephalopathy or 
chorioretinopathy [1, 3]. EHV-3 is the cause of equine 
coital exanthema (ECE), a genital disease that is trans-
mitted venereally. This disease is characterized by the 
development of papules, vesicles, pustules and ulcers in 
the mucosa of the vagina and vestibula of mares and the 
penis and prepuce of stallions, in the skin of the perineal 
region of the mares and occasionally on the skin of the 
lips and mucosa of the upper respiratory tract [2, 4, 5]. 
Both EHV-1 and EHV-3 are members of the subfamily 
Alphaherpesvirinae with about 150 kilobases double-
stranded DNA genome, consisting of 76 unique open 
reading frames [6, 7]. However, antigenically, genetically 
and pathogenetically, EHV-1 and EHV-3 are significantly 
different [2].
Latently infected equines are important biological res-
ervoirs for EHV-1 [8, 9] and EHV-3 [2, 10]. The periodic 
virus reactivation from latency leads to the production 
of infectious virus that serves as a source of infection [1, 
10]. EHV-1 is transmitted to susceptible equids through 
direct contact with virus-laden respiratory secretions or 
indirectly with fomites [1]. Although EHV-3 is primarily 
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transmitted through coitus, contaminated fomites have 
also been implicated in its spread [11].
After initial infection, EHV-1 replicates in mucosal 
epithelial cells of the upper respiratory tract and causes 
erosions and viral shedding into the environment [1, 12]. 
The virus then invades the underlying lamina propria by 
infected immune cells [12–14]. Hereafter, EHV-1 dis-
seminates throughout the body using infected mononu-
clear cells as Trojan horses. The cell-associated viremia 
allows the virus to arrive and replicate at the endothelial 
cells of the target organs, which leads to vasculitis and 
ischemic thrombosis [15]. In contrast, EHV-3 replicates 
in the stratified epithelium of epidermal tissues present 
at the mucocutaneous margins and skin [2]. Destruction 
of the epithelium by the lytic virus infection elicits a vig-
orous, localized inflammatory response that gives rise to 
the formation of characteristic cutaneous lesions of ECE 
[2]. Infertility and abortion associated with EHV-3 have 
not been reported [16, 17]. However, the disease has a 
negative impact in the equine industry as a result of the 
forced, temporary disruption of the mating activities of 
affected stallions and mares [2, 18].
Different strains of EHV-1 have a different pathologi-
cal outcome, which is correlated with the variation in the 
ability to disseminate and establish infection at vascular 
endothelial cells of the target organs such as the endome-
trium, the central nervous system and the eye [3, 19]. The 
respiratory mucosal surface plays a major role in EHV-1 
primary replication and transmission [13]. Variation in 
the structural barriers, microenvironment and the com-
position of available target cells on mucosal tissues may 
dramatically influence the efficiency of EHV-1 replica-
tion. Previous studies have shown the invasion mecha-
nisms of EHV-1 in the equine respiratory mucosa using 
nasal explants [20] and an in vivo experiment [14]. It was 
demonstrated that during infection of epithelial cells, 
EHV-1 is infecting mucosal monocytes and is hijack-
ing these cells to invade the deeper connective tissues. 
Despite these studies, little is known about the replica-
tion efficiency of EHV-1 strains in the vaginal epithelial 
mucosa, which could serve as an alternative EHV-1 por-
tal of entry.
EHV-3 is highly host specific. It replicates only in cell 
lines derived from equids and a laboratory animal model 
has not been identified for EHV-3 infection [2, 21]. To 
date, experimental studies with EHV-3 have solely been 
done in the natural hosts, equids. To study early events 
of EHV-3 mucosal invasion, an alternative in vitro model 
would be very valuable. Previously, the replication char-
acteristics of other equine alphaherpesviruses, EHV-1 
and EHV-4, have been studied in respiratory mucosa 
explants [20, 22]. The replication of EHV-4 was restricted 
to the epithelial cells, whereas EHV-1 was also infecting 
mucosal leukocytes. However, the replication kinetics 
and the invasion characteristics of EHV-3 in mucosae are 
still not known.
Therefore, this study was designed to compare the rep-
lication kinetics and the invasion characteristics of the 
neuropathogenic and abortigenic strains of EHV-1 and 
EHV-3 in the nasal and vaginal mucosae using ex vivo tis-
sue cultures.
Materials and methods
Tissue collection
The nasal and vaginal tissues were obtained from healthy 
horses with an estimated age of 5–10 years after slaugh-
ter in the abattoir. The absence of recent EHV-1 and 
EHV-3 infection was demonstrated by the absence of 
cytopathic effect up on inoculation of rabbit kidney 13 
cell and equine dermal cell lines with tissue suspensions 
(10% W/V). A complement-dependent seroneutraliza-
tion test was also performed on the serum to determine 
EHV-specific antibody titres. The stage of the reproduc-
tive cycle was also evaluated by visual inspection of the 
ovaries. All the animals were found to be in diestrus.
All the tissues were collected with transport medium 
containing phosphate buffered saline (PBS) supple-
mented with 1  μg/mL gentamycin (Invitrogen, Paisley, 
UK), 1  mg/mL streptomycin (Certa, Braine l’Alleud, 
Belgium), 1 mg/mL kanamycin (Sigma, St. Louis, MO, 
USA), 1000 U/mL penicillin (Continental Pharma, Puurs, 
Belgium) and 5  μg/mL amphotericin B (Bristol-Myers 
Squibb, New York, USA). All collected tissues were 
placed in a cooler containing ice for transport to the 
laboratory and were processed immediately after arrival. 
The mucosae were stripped from the underlying tissues 
and dissected into explants of approximately 25 mm2.
Air–liquid culture model
Cultivation of the explants was performed according to 
the protocol as previously described [23, 24] with some 
modifications. Briefly, the explants were cultured using 
fine-meshed gauze, on 6-well tissue-culture plate, in an 
air–liquid interface with epithelium facing upwards. The 
explants were cultured with serum free medium consist-
ing of a 1:1 mixture of Roswell Park Memorial Institute 
medium (RPMI GlutaMAX™) (Invitrogen) and Dul-
becco’s Modified Eagle’s Medium (DMEM GlutaMAX™) 
(Invitrogen) supplemented with 1  μg/mL gentamycin 
(Invitrogen), 0.1 mg/mL streptomycin (Certa) and 100 U/
mL penicillin (Continental Pharma). To mimic an air-
interface as in the living animals, the explants were cov-
ered with a thin-film of medium and maintained at 37 °C 
in an atmosphere containing 5% CO2.
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Evaluation of tissue viability
Tissue viability was monitored by evaluating ciliary beat-
ing of the epithelial cells of the nasal explants using light 
microscope and by quantifying the apoptotic cells using 
in  situ cell death detection kit (Roche Diagnostics Cor-
poration, Basel, Switzerland). Terminal deoxynucleotidyl 
transferase mediated dUTP nick end labeling (TUNEL), 
preferentially labels DNA strand breaks generated dur-
ing apoptosis. The test was performed according to the 
manufacturer’s guidelines on cryosections preserved in 
methocel® (Sigma) at 0, 24, 48, 72 and 96 h of cultivation. 
In both the epithelium and lamina propria, the percent-
age of TUNEL-positive cells was quantified in five ran-
domly chosen fields of 100 cells each. TUNEL-positive 
cells were detected and enumerated by fluorescence 
microscopy (Leica DMRBE, Wild Leitz GmbH, Heidel-
berg, Germany).
Virus strains used for infections of the explants
Two Belgian EHV-1 strains, representing neuropatho-
genic and abortigenic variants of EHV-1, were used in 
this study. These strains were typed by sequencing the 
DNA polymerase gene of EHV-1 as previously described 
[25]. The abortigenic EHV-1 strain 97P70 which was 
isolated from an aborted fetus in 1997 and the neu-
ropathogenic strain 03P37 which was isolated from the 
peripheral blood mononuclear cells of paralytic horses 
in 2003, were used. EHV-1 virus stocks used for inocula-
tion of the explants were at the 6th passage; four passages 
in equine embryonic lung cells and two subsequent pas-
sages in rabbit kidney 13 cells.
The EHV-3 strain 04P57 which was isolated from a 
horse with typical ECE lesions in Belgium in 2004, was 
used in this experiment. The virus stock used for inoc-
ulation was at the second passage in equine embryonic 
kidney cells. Genetic and pathogenic differences between 
EHV-3 strains have not been described and therefore, 
only one EHV-3 strain was included in this study.
Inoculation of the explants
After 24  h of culture, explants were inoculated with the 
strains of EHV-1 and EHV-3 by submerging the tissue in 
1 mL of inoculum containing 106.5 TCID50 for 1 h at 37 °C 
and 5% CO2. After incubation, explants were washed 
twice with warm medium and transferred back to the 
original 6-well plates containing gauze and medium. At 0, 
24, 48 and 72 h post inoculation (pi), explants were col-
lected, embedded in methylcellulose medium (Methocel® 
MC, Sigma-Aldrich, St. Louis, USA) and frozen at −70 °C.
Immunofluorescence staining and plaque analysis
A double immunofluorescence staining was performed to 
detect and localize EHV-1 and EHV-3-infected cells at 0, 
24, 48 and 72 h pi in 100 consecutive 16 µm cryosections 
of the explants. The cryosections were fixed with 100% 
methanol for 20 min at −20 °C. The basement membrane 
(BM) of the tissues was stained with monoclonal mouse 
anti-collagen VII antibodies (Sigma-Aldrich), followed by 
Texas red-labeled goat anti-mouse antibody (Invitrogen). 
Biotinylated equine polyclonal anti-EHV-1 IgG antibod-
ies [26] were used to label the EHV-1 viral antigens and 
biotinylated rabbit polyclonal anti-EHV-3 IgG antibod-
ies to label EHV-3 viral antigens. Next, fluorescein iso-
thiocyanate (FITC) labeled streptavidin (Invitrogen) was 
added. Mock-inoculated cryosections were stained as 
negative controls. In each steps, cryosections were incu-
bated at 37 °C for 1 h and were washed afterwards three 
times with PBS. Hoechst 33342® staining (molecular 
probes) was performed to visualize the nuclei of the cells. 
Then, the cryosections were mounted with glycerol con-
taining antifading agent 1, 4-Diazobicyclo-(2, 2, 2-octane 
(DABCO®). The plaques were visualized using a confo-
cal fluorescence microscope (Leica DMRBE, Wild Leitz 
GmbH, Heidelberg, Germany). The number of plaques 
per 8  mm2 explants and the plaques size were quanti-
fied using Leica LAS AF Lite software. The plaques on 
the borders and edge of the explants were excluded from 
analysis.
Identification and quantification of single infected cells
To identify and quantify EHV-1 and EHV-3 infected 
single cells, a double immunofluorescence staining was 
performed. At each collection time point, 10  μm-thick 
cryosections of tissue explants were fixed in 100% metha-
nol at −20 °C for 20 min. For each tissue and each time 
point, 20 cryosections were stained for each cell sur-
face marker separately. Monoclonal antibodies DH59B 
(VMRD, USA), UC F6G-3 (California University, Davis, 
USA) and 1.9/3.2 (VMRD, USA) were used as mark-
ers for CD172a cells of the monocyte lineage, CD3 cells 
(pan T-lymphocytes) and IgM cells (B-lymphocytes), 
respectively. Then, the cryosections were incubated 
with Texas Red®-labeled goat anti-mouse IgG antibod-
ies (Invitrogen). In the second step, EHV-1 and EHV-3 
viral proteins were stained with biotinylated equine poly-
clonal anti-EHV-1 IgG antibodies [26] and biotinylated 
rabbit polyclonal anti-EHV-3 IgG antibodies, respec-
tively, followed by streptavidin-FITC (Invitrogen). Sec-
tions of mock-inoculated explants and isotype matched 
irrelevant control antibodies were used as negative con-
trols. In each step, cryosections were incubated at 37 °C 
for 1  h and washed three times with PBS. The nuclei 
were counterstained with Hoechst 33342® for 10  min. 
At each time point, the percentage of EHV-1 infected 
cells that are marker positive cells were calculated from 
20 cryosections of 10 µm thick for each specific marker. 
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All the cryosections were analyzed by confocal micros-
copy (Leica DMRBE, Wild Leitz GmbH, Heidelberg, 
Germany).
Statistical analysis
The data were analyzed using SPSS version 20 software 
(SPSS Inc, Chicago, USA). Differences between the 
strains, tissues and among time points were compared by 
the analysis of variance (ANOVA) with post hoc multiple 
comparisons. Mann–Whitney test was also used as non-
parametric test. All data are expressed as means with 
standard deviation (SD) of three independent experi-
ments. Differences were considered statistically signifi-
cant when P value was <0.05.
Results
Tissue viability
The viability of the cells in the nasal and vaginal explants 
were evaluated using TUNEL staining to detect DNA frag-
mentation associated with apoptotic cell death at 0, 24, 48, 
72 and 96 h of cultivation. During the ex vivo tissue cul-
tivation, the number of apoptotic cells in the epithelium 
slightly, but not significantly, increased over time. The per-
centage of TUNEL positive cells in the epithelium of the 
nasal and vaginal mucosae was 1.7 ±  0.2 and 1.9 ±  0.1, 
respectively, at 96  h of cultivation (Table  1). In the epi-
thelium of the nasal mucosa, ciliary beating was observed 
during the whole experiment (up to 96 h of cultivation).
Invasion characteristics
The invasion characteristics of EHV-1 and EHV-3 were 
assessed in the nasal and vaginal mucosae at 0, 24, 48 
and 72  h pi. In mock-infected explants, plaques were 
not observed throughout the experiments. Both strains 
of EHV-l and EHV-3 replicated in a plaquewise manner 
and spread laterally on the epithelium. The plaques in the 
epithelium were already found at 24 h pi, their sizes sig-
nificantly increased over time and did not cross the BM 
at all the time points pi. However, EHV-1 and EHV-3 
exhibited different invasion characteristics. EHV-1 infects 
mononuclear immune cells to invade the lamina propria 
(Figure  1). In contrast, EHV-3 replication was restricted 
to the epithelium of the nasal and vaginal mucosae, where 
the virus neither breaches the BM nor infects individual 
monocytic immune cells at all time points pi (Figure 2).
Number of plaques
The number of plaques induced by EHV-1 and EHV-3 on 
8 mm2 of explants was counted at 24, 48 and 72 h pi. In 
both mucosae, the average number of plaques induced by 
both strains of EHV-1 significantly increased (P  <  0.05) 
over time. In the nasal mucosa, no significant difference 
(P > 0.05) was observed in the average number of plaques 
between both EHV-1 strains (Figure  3). However, the 
average number of plaques in the vaginal mucosa was 
significantly higher (P < 0.05) with the abortigenic strain 
97P70 compared to the neuropathogenic strain 03P37 at 
all time points pi. Overall, the average number of plaques 
counted in the nasal mucosa was significantly higher 
(P < 0.05) than in the vaginal mucosa.
With EHV-3, the average number of plaques in the 
nasal mucosa slightly, but not significantly (P  >  0.05) 
increased over time. However, the average number of 
plaques in the vaginal mucosa significantly increased 
(P  <  0.05) between 24 and 72  h pi. Overall, the average 
number of plaques was significantly higher (P < 0.05) in 
the vaginal mucosa than in the nasal mucosa at 24 and 
72 h pi (Figure 3).
Plaques size
Both strains of EHV-1 had a different potential to spread 
from cell-to-cell in the nasal and vaginal mucosae. In 
the nasal mucosa, the neuropathogenic EHV-1-induced 
plaques enlarged significantly (P  <  0.05) over time with 
an average of 77.9 ± 22.1 µm at 24 h pi, 140.1 ± 45.0 µm 
at 48 h pi and 216.1 ± 44.9 µm at 72 h pi. Likewise, the 
size of the plaques induced by the abortigenic strain sig-
nificantly (P < 0.05) increased over time with an average 
of 68.9 ± 15.8 µm at 24 h pi, 166.9 ± 52.3 µm at 48 h pi 
and 245.5 ± 52.3 µm at 72 h pi. However, the average sizes 
of the plaques were not significantly different (P  >  0.05) 
between both EHV-1 pathotypes (Figure  3). In the vagi-
nal explants, the size of the plaques induced by the abor-
tigenic strain significantly increased (P  <  0.05) between 
48 and 72  h pi with an average of 125  ±  41.7  µm and 
192  ±  89.5  µm, respectively. Similarly, the plaque size 
slightly, but not significantly (P > 0.05) increased over time 
with the neuropathogenic strain. In contrast, the average 
size of the plaques induced by the neuropathogenic strain 
Table 1 Percentage of TUNEL-positive cells in the epithe-
lium and lamina propria of the nasal and vagina mucosae 
at different time points of cultivation.
Percentage of TUNEL-positive cells at indicated 
time points of cultivation
0 h 24 h 48 h 72 h 96 h
Nasal mucosa
 Epithelium 0.3 ± 0.1 0.4 ± 0.2 0.7 ± 0.1 1.3 ± 0.1 1.7 ± 0.2
 Lamina  
propria
0.7 ± 0.1 1.1 ± 0.3 2.5 ± 0.3 3.1 ± 0.2 4.2 ± 0.2
Vaginal mucosa
 Epithelium 0.4 ± 0.2 0.7 ± 0.1 1.4 ± 0.3 1.7 ± 0.1 1.9 ± 0.1
 Lamina  
propria
0.9 ± 0.2 1.3 ± 0.4 3.4 ± 0.5 3.6 ± 0.6 6.2 ± 0.4
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was significantly smaller (P < 0.05) when compared to the 
abortigenic strain at all time points pi (Figure 3).
Overall, the average sizes of the plaques induced by 
both EHV-1 strains were significantly larger (P < 0.05) in 
the nasal mucosa than in the vaginal mucosa.
With EHV-3, the average size of the plaques signifi-
cantly increased (P  <  0.05) over time in both the nasal 
and vaginal explants. The average size of EHV-3-induced 
plaques in the vaginal mucosa was 56.5  ±  20.1  µm, 
84.5 ± 33.8 µm and 149.2 ± 53.0 µm at 24, 48 and 72 h 
Nasal mucosa
Vaginal mucosa
0 h 24 hr 48 h 72 h
24h 48h 72h
03P37
0h
97P70
97P70
03P37
0 h 24 h 48 h 72 h
Figure 1 Confocal photomicrographs showing EHV-1-induced plaques in nasal and vaginal explants inoculated with EHV-1 03P37 
and EHV-1 97P70. The BM is visualized using mouse anti-collagen VII and goat anti-mouse Texas Red® antibodies. The viral antigens are detected 
using biotinylated equine polyclonal anti-EHV-1 IgG antibodies and striptavidin-FITC®. Scale bar 100 µm.
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pi, respectively. Similarly, an average of 35.7 ± 12.5 µm 
(24 h pi), 59.6 ± 9.1 µm (48 h pi) and 100.8 ± 41.5 µm 
(72 h pi) plaque size was recorded in the nasal mucosa. 
Overall, the average size of the plaques induced by 
EHV-3 was significantly higher (P < 0.05) in the vaginal 
mucosa, compared to the nasal mucosa at all time points 
pi (Figure 3).
Identification and quantification of single infected cells
Single EHV-1 and EHV-3-infected cells underneath 
the BM of the nasal and vaginal mucosa tissues were 
assessed. In both mucosal tissues, EHV-3-infected cells 
underneath the BM were totally not detected at all the 
time points pi. In both mucosae, EHV-1-infected cells 
was already visible starting from 24  h pi with the neu-
ropathogenic strain and from 48  h with the abortigenic 
strain (Figure 4).
The percentage of abortigenic EHV-1-infected indi-
vidual monocytic cells was twofold lower in the vaginal 
mucosa than in the nasal mucosa. Similarly, up to five-
fold lower percentage of neuropathogenic EHV-1-in-
fected individual monocytic cells was recorded in the 
vaginal mucosa than in the nasal mucosa. Regardless of 
the tissues and strains of EHV-1, CD172a+ cells from 
the monocytic lineage were the predominant cells type 
infected, followed by CD3+ T-lymphocyte. EHV-1 infects 
IgM+ cells (B-lymphocytes) to a much lesser extent 
(Figure 5).
Discussion
Neuropathogenic and abortigenic EHV-1 strains, that 
display different diseases are circulating in the field. 
The mucosal surface of the upper respiratory tract plays 
a major role in EHV-1 replication and transmission. 
Despite several studies conducted on the replication 
kinetics and characteristics of EHV-1 on the tissues of 
the upper respiratory tract, the replication efficiency of 
both pathotypes in the vaginal mucosa was never studied 
before. EHV-3 has been associated with both genital and 
respiratory diseases, however the underlying pathogen-
esis remains poorly understood, due in part to the lack 
of appropriate models to study virus-host interactions. 
Therefore, in this study, ex  vivo respiratory and vaginal 
mucosa explant cultures were developed to gain more 
insight into the replication kinetics and invasion charac-
teristics of the neuropathogenic and abortigenic strains 
of EHV-1 and to elucidate the pathogenesis of EHV-3 
in the nasal and vaginal mucosae, target organs for virus 
entry and replication. The explants, directly derived from 
the upper respiratory tract and the vagina of the horses, 
were maintained in an air–liquid interface for up to 96 h 
with little change in the viability of the cells as evaluated 
by ciliary beating and the number of apoptotic cells. The 
mucosal explant models showed an intact 3D structure 
and contained all resident mucosal target cells and con-
sequently is ideal to study the virus-host interactions at 
the site of infection. These explants from slaughterhouse 
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Figure 2 Confocal photomicrographs showing EHV-3-induced plaques in the nasal and vaginal mucosa infected with EHV-3 04P57. 
The BM is visualized using mouse anti-collagen VII and goat anti-mouse Texas Red® antibodies. The viral antigens are detected using biotinylated 
rabbit polyclonal anti-EHV-3 IgG antibodies and streptavidin-FITC®. Scale bar 100 µm.
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horses replace experimental animals and is, as such, in 
line with the 3Ds of animal welfare.
In the present study, both types of EHV-l and EHV-3 
replicated in a plaquewise manner and spread laterally 
on the epithelium. The plaques were already present on 
the epithelium starting from 24 h pi and their sizes sig-
nificantly increased over time. The plaques did not cross 
the BM to infect the underlying tissues at all time points 
pi. However, the invasion via single infected leukocytes 
in the underlying connective tissue was different. EHV-1 
breached the BM and invaded the lamina propria using 
infected mononuclear immune cells. In contrast, EHV-3 
replication was restricted to the epithelial cells, where 
the virus neither breached the BM in a direct way nor 
infected individual immune cells to invade the lamina 
propria. This non-invasive behavior of EHV-3 is compa-
rable with what has been seen with EHV-4 [22], but in 
contrast with other members of alphaherpesviruses such 
as pseudorabies virus (PRV) [27], bovine herpesvirus-1 
(BoHV-1) [24], herpes simplex virus-1 (HSV-1) [28], 
canine herpesvirus-1 (CaHV-1) (Yewei Li, unpublished 
data), feline herpesvirus-1 (FeHV-1) [29] and infectious 
laryngotracheitis virus (ILTV) [30], which breach the BM 
and infect the underlying connective tissue. For PRV, it 
was shown that a cellular serine protease is responsible 
for this phenomenon [31].
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Figure 3 Replication kinetics of EHV-1 (A and B) and EHV-3 (C) in the nasal and vaginal explants. The number of plaques/8 mm2 explants 
and the plaque size are shown. Data represent mean ± SD of triplicate independent experiments. Significant differences are indicated by the use of 
different letters.
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In our study, both strains of EHV-1 types have remark-
ably higher replication kinetics in the nasal mucosa 
compared to the vaginal mucosa as evaluated by the 
number of plaques counted, the size of the plaques, and 
the amount of infected individual mononuclear immune 
cells. This suggests that the nasal mucosa is the primary 
tissue of preference for EHV-1 replication and entry into 
its host. Both EHV-1 types replicated with comparable 
kinetics in the nasal mucosa at all time points pi. This 
result is consistent with the earlier report in the respira-
tory mucosa explants study [20], where no differences 
were observed in the replication kinetics between both 
EHV-1 types. Despite the fact that EHV-1 has a main 
tropism for the respiratory mucosa, the vaginal mucosa 
is able to support replication. However, the magnitude 
of replication in the vaginal mucosa was significantly dif-
ferent between the two EHV-1 strains. The neuropatho-
genic strain replicated less efficiently than the abortigenic 
strain and at 72 h pi a lot of non-infected basal cells were 
observed between the cluster of infected epithelial cells 
and the BM for the neuropathogenic strain but not for 
the abortigenic strain. Several reasons may be responsi-
ble for this observation. Gryspeerdt et  al. [14] reported 
that after 3 days of infection the production of interferon 
limits EHV-1 replication in the epithelium of the upper 
respiratory tract. Maybe the same defense mechanism is 
CD3+
CD172a+
IgM+
EHV-1+ Merged
Merged
Merged
EHV-1+
EHV-1+
100µm 10µm
Figure 4 Representative confocal microscope images of marker positive-EHV-1-infected cells in the vaginal mucosa. The explants were 
sectioned (10 µm) and co-immunostained for EHV-1 infected cells (green) and marker positive cells (red). White dotted line indicates the BM. White 
arrowheads shows double positive cells.
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activated in the vaginal mucosa. EHV-1 infection induces 
high antiviral interferon-α levels, which is critical in the 
host innate immune response [32]. Another possible 
explanation for the difference in replication efficiency 
observed between the two EHV-1 strains might be asso-
ciated with viral genetic factors. Goodman et  al. [33] 
reported that EHV-1 virulence and tissue tropism in the 
natural host are linked with the function of the DNA pol-
ymerase. Indeed, a single point mutation in this enzyme 
has been claimed to be responsible for the neurotropism. 
It would now be very interesting to determine if the 
same point mutation in this enzyme is also determining 
the level of EHV-1 replication in the vaginal mucosa. It 
is very well possible that this point mutation is gener-
ally affecting the replication of EHV-1 in the different 
mucosae of the genital tracts (endometrium and vaginal 
mucosa).
In this study, although we clearly demonstrated that 
both EHV-1 types are capable of replicating in the 
mucosa of the vaginal epithelium, the extent of replica-
tion is much higher with the abortigenic strain compared 
with the neuropathogenic strain. Previous reports indi-
cated that EHV-1 has been isolated from male genital 
organs [34] and is shed with the semen and the sperm 
cells [35–37]. When we combine the latter reports with 
our findings, we could propose a possible venereal trans-
mission of EHV-1 via the semen, which was largely 
ignored before. The venereal transmission have been 
well documented for other alphaherpesviruses such as 
EHV-3 [2], BoHV-1 [38, 39], PRV [40] and CaHV-1 [41]. 
Therefore, our study highlights an important insight that 
should be further investigated in the field.
In our study, although both the nasal and vaginal 
mucosae infected by EHV-3, the replication kinetics is sig-
nificantly different. The sizes of EHV-3-induced plaques 
are significantly higher in the vaginal mucosa than the 
nasal mucosa. This replication advantage of EHV-3 in the 
vaginal mucosa might be associated with the virus tis-
sue tropism, as it has a higher affinity to affect the geni-
tal organs under natural conditions. Although, post-coital 
infection of the EHV-3 is the general route of transmis-
sion, non-venereal transmission to the nasal mucosa has 
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Figure 5 Percentage of EHV-1-infected individual cells. The cells were identified as monocytic cells (CD172a+), pan T-lymphocytes (CD3+) and 
B-lymphocytes (IgM+) per 20 sections of the nasal and vaginal mucosal explant infected with EHV-1 03P37 (A) and EHV-1 97P70 (B). Lines show the 
mean ± SD of three independent experiments.
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been reported via genitonasal contact and contaminated 
objects [2, 42]. In the current study, EHV-3 replication 
was restricted to the epithelium mucosae, where the virus 
neither breached the BM to invade the lamina propria 
nor infected individual mononuclear immune cells. This 
localized replication behavior might limit the EHV-3 dis-
semination via systemic blood circulation. In-vivo EHV-3 
infection destroys the epithelium and elicits a vigorous, 
localized inflammatory response [2] and systemic dis-
semination of the virus is exceptional [42]. Whether host 
factors or viral factors inhibit the virus to infect individual 
immune cells and to invade the underlying tissue is not 
clear and deserves further investigation.
In the current study, the neuropathogenic strain infects 
a higher percentage of monocytic cells in the nasal 
mucosa when compared to the abortigenic strain. This 
result is in line with the previous report made by Van-
dekerckhove et  al. [20] in the nasal explants study and 
Gryspeerdt et  al. [14] in an in  vivo study. However, the 
neuropathogenic strain infects a lower percentage of cells 
in the vaginal mucosa than the abortigenic strain of EHV-
1. These results suggest that the number of single infected 
cells may vary with the mucosa type infected with EHV-1. 
With both EHV-1 types, two-to-five-fold lower percent-
age of infected monocytic cells were found in the lamina 
propria of the vaginal mucosa than in that of the nasal 
mucosa. Infected individual cells underneath the BM were 
visible already at 24 h pi with the neuropathogenic strain, 
and at 48 h pi with the abortigenic strain. The monocytic 
lineage cells, which express surface marker CD172a, were 
the predominant cell type infected with EHV-1, inde-
pendent of the strain and tissue. This is in agreement 
with the previous report in the nasal explants [20], in an 
in vivo experiment [14], and in peripheral blood mononu-
clear cells [43, 44]. This cell marker is expressed in equine 
monocytes, macrophages, dendritic cells and granu-
locytes [45, 46]. Recently, Baghi et  al. [47] reported that 
isolated equine nasal mucosal CD172a+ cells resemble 
immature dendritic cells. The dendritic cells in the periph-
ery capture and process antigens, express lymphocyte 
co-stimulatory molecules, migrate to lymphoid organs 
and secrete cytokines to initiate immune responses [48]. 
CD3+ T- lymphocytes were also an important cell type 
infected with EHV-1. IgM+ cells (B- lymphocytes) were 
infected to a much lesser extent.
In conclusion, EHV-1 and EHV-3 exhibited differ-
ent invasion characteristic. Both viruses replicated in a 
plaquewise manner and spread laterally on the epithe-
lium. EHV-3-induced plaques are restricted to the epi-
thelium of the nasal and vaginal mucosae and the virus 
neither breaches the BM nor infect individual immune 
cells at all time points pi. In contrast, EHV-1 invades the 
underlying connective tissue by infecting mononuclear 
immune cells. Our ex  vivo explant models provided an 
important new insight that should be further investigated 
in order to better understand the underlying mechanisms 
and in vivo relevance.
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